NCT06656039Completed
A Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma
Development and Validation of a Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma: a Multicenter Cohort Study
Source: ClinicalTrials.gov · Last updated 24 Oct 2024
Brief summary (registry, in English)
The main goal of this observational study is to construct a predictive recurrence model for renal clear cell carcinoma through an artificial intelligence multimodal algorithm, which will improve the prognosis and survival time of ccRCC patients by helping clinicians to formulate individualised follow-up and to screen for appropriate adjuvant therapy candidates.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1200 (actual)
- First submitted
- 20 Oct 2024
- Start date
- 1 Jan 2024
- Primary completion date
- 10 Oct 2024
- Lead sponsor
- RenJi Hospital
- Diseases
- Kidney cancer
- NCT number
- NCT06656039
What you commit to
- Study type: Observational
- Participants enrolled: 1200
- From 1 Jan 2024 to the primary completion date, 10 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- The patient's tumour type cannot be determined on the basis of histopathological sections
- Simultaneous combination of primary tumours at other sites;
- No regular follow-up imaging data
- Cases in which other factors led the investigator to believe that enrolment was inappropriate
- Cases that met all the inclusion criteria of the appeal and did not meet all the exclusion criteria were selected for this study
Who the study is looking for
- Patients with malignant renal tumours must have postoperative pathological confirmation of renal clear cell carcinoma with pathological TNM stage Ⅰ-Ⅲ;
- Have available preoperative imaging
- Have available post-operative pathological paraffin samples or HE-stained tissue sections
- Must agree to and be able to comply with the study's visit schedule and other requirements as specified in the protocol, including follow-up visits by telephone
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| RenJi Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.